|| List of recent Adverse Event-related patents
|Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone|
Presented herein are methods for treatment or prevention of opioid induced constipation by administration of oral compositions of methylnaltrexone. The methods are based, at least in part, on the identification of subjects that are particularly susceptible to such treatment and optimal dosages of such oral compositions to treat or prevent opioid induced constipation and, further, to minimize the occurrence of adverse events associated with such treatment..
|Computer algorithms and methods for product safety|
The invention comprises systems, methods and a computerized, data management device for creating and using data relating to a medical or non-medical product or device to enhance the safety of the product or device. A vast amount of data regarding adverse events associated with a particular product or device is analyzed to identify new essential adverse events associated with the product or device.
|Antibodies selective for cells presenting egfr at high density|
Herein described are antibodies to epidermal growth factor receptor (egfr) having an egfr binding affinity that is sufficient to kill disease cells presenting egfr at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells..
|Prevention of adverse effects caused by cd3 specific binding domains|
The present invention relates to a glucocorticoid (gc) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a cd3 binding domain. Kits comprising a gc, a cd3 binding domain and instructions for use which indicate that the gc is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said cd3 binding domain, are also disclosed..
|Direct reporting of adverse events|
Systems, methods, and computer readable media are described for communicating an adverse event report directly to an end-user receiving party and tracking one or more adverse event reports. An adverse event may be detected manually or automatically by a system and an electronic adverse event reporting form presented to a user with one or more data fields pre-populated with data from a patient's electronic health record (ehr).
|Intragastric balloon shell materials and construction|
An intragastric balloon with a 12-month lifespan. The intragastric balloon has a shell made of a material with as good as or better than initial mechanical properties of previous materials; i.e.
|Method for treatment of acne using pharmaceutical compositions of clindamycin|
The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions.
|Adverse event-resilient network system|
An adverse event-resilient network system consisting of autonomously powered and mobile nodes in communication with each other either through radio, light or other electromagnetic signals or through a physical connection such as through wiring, cables or other physical connected methods capable of carrying information and communication signals. The nodes powered by an energy generator comprising multiple data, information and voice gathering, receiving and emitting devices as well as mechanical, optical and propulsion devices..
|Algorithm for predicting and mitigating adverse events|
A patient support apparatus includes a control system operable to gather physiological information about a patient supported on the patient support apparatus. The information may be gathered from sensors, a user interface, or a hospital information system.
|Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor|
This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment.
|Risk factors and prediction of adverse events|
Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery.. .
|Altering pharmacokinetics of pirfenidone therapy|
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
|Method of providing pirfenidone therapy to a patient|
The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone.
|Method of treating acne|
An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion.
|Signal detection algorithms to identify drug effects and drug interactions|
An algorithm according to an embodiment of the present invention provides for latent signal detection of adverse events. Embodiments infer the presence of adverse drug events from large observational databases housed by the fda, who, and other governmental organizations.
|Systems and methods for de-risking patient treatment|
The present disclosure describes systems and methods for de-risking patient treatment by identifying medications or combinations of medications to be contraindicated for a specific indication. An analyzer executed by a processor of a computing device from a user may receive an identification of an indication (e.g.
|Systems and methods for personalized de-risking based on patient genome data|
The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein.
|Systems and methods for using adverse event data to predict potential side effects|
The present disclosure describes systems and methods for predicting a likely side effect profile for even new, untested medications. A predicted side effect profile may be generated based on intersections of side effect profiles of other medications that affect the same or related molecular entities, such as the nearby target proteins, involve the same pathways, or are otherwise similarly related.
|Systems and methods for identifying unknown drug targets via adverse event data|
The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug.
|Compositions for treating heartworm infestation|
The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against dirofilaria parasites, without the risks for secondary adverse events of conventional formulations.
|Systems and methods for assessing medical record complexity and risk of adverse events|
Methods and apparatus for analyzing an electronic medical record (emr) are provided. The method includes assigning to at least one document in the emr, a first value, wherein the assigning is based, at least in part, on a number of characters and/or a number of digits included in each document of the at least one document, determining a second value, wherein the second value is determined based, at least in part, on the first values, determining whether the second value is above a threshold value, and outputting an indication that the second value is above the threshold value.
|Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics|
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
|System and method for providing insurance|
A system and method for providing post-operative insurance in a surgical procedure involving implantation of a foreign material into a human body includes underwriting an insurance policy to cover an adverse event resulting from the procedure that may occur from a completion date of the procedure up to at least one year from the completion date of the procedure from a completion date of the procedure. The method further includes determining eligibility for enrollment of a patient undergoing the procedure and providing the insurance policy to the patient if the patient is eligible to enroll.
|Prediction and recognition of acute kidney injury after surgery|
Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury aki as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (l-fabp) in a sample, such as a urine-sample of a subject; comparing the amounts of the l-fabp with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject..
|Compositions and methods for treating obesity and obesity-related conditions|
A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.. .
|Controller for a medical products storage system|
A medical product storage device includes a controller that operates an access control system to limit access to a storage space of the medical product storage device. The controller monitors a temperature in the storage space and other operating parameters of the medical product storage device.
|Pharmaceutical compositions and methods of use|
The present invention provides a pharmaceutical composition comprising a chemical compound or a herb extract or the combination having at least one of the activities of antiviral, antibacterial, antifungal, anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, for the treatment and prevention of a disease of a mammal. The pharmaceutical composition is to be delivered into the hard-to-reach sinuses of a mammal by using a unique sinonasal delivery device.
|Sinonasal specimen collection kit and use|
The present invention additionally provides a kit for collecting the sinonasal specimen to analyze which pathogenic microbes cause a disease in a mammal, how to test the drug sensitivity against the infectious microbes in sinonasal cavities, and to help the selection of a pharmaceutical composition to selectively treat a disease of a mammal. The present invention also provides a pharmaceutical composition comprising a chemical compound or a herb extract or the combination having at least one of the activities of antiviral, antibacterial, antifungal, anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, for the treatment and prevention of a disease of a mammal.
|Quinine dosage forms and methods of use thereof|
Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc..